Fig. 1: Establishing a biobank of ovarian cancer ex vivo models.
From: A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
a Patient timelines showing age at diagnosis and death, treatments and biopsy collections. b Workflow for processing and storage of stromal and tumour fractions. (RBC red blood cells, WBC white blood cells, LN2 and −80 °C specifies long-term storage, OCMI ovarian carcinoma modified Ince medium, NGS next-generation sequencing, VEGFi vascular endothelial growth factor inhibitor). See also Supplementary Fig. 1 and Supplementary Tables 1 and 2.
